Cocrystal Pharma, Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

COCP$1.11+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

	September 30, 2025	December 31, 2024
(unaudited)
Assets
Current assets:
Cash	$7,729	$9,860
Restricted cash	75	75
Tax credit receivable	513	1,215
Prepaid expenses and other current assets	465	430
Total current assets	8,782	11,580
Property and equipment, net	106	153
Deposits	90	29
Operating lease right-of-use assets, net (including $115 and $152 respectively, to related party)	1,468	1,694
Total assets	$10,446	$13,456
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$1,194	$2,127
Current maturities of operating lease liabilities (including $54 and $49 respectively, to related party)	326	301
Total current liabilities	1,520	2,428
Long-term liabilities:
Operating lease liabilities (including $63 and $104 respectively, to related party)	1,257	1,505
Total liabilities	2,777	3,933
Commitments and contingencies (Note 7)	-	-
Stockholders’ equity:
Common stock, $0.001 par value 100,000 shares authorized as of September 30, 2025 and December 31, 2024; 13,041 and 10,174 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	13	10
Additional paid-in capital	347,479	342,931
Accumulated deficit	(339,823)	(333,418)
Total stockholders’ equity	7,669	9,523
Total liabilities and stockholders’ equity	$10,446	$13,456

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.